表紙
市場調查報告書

全球抗憂鬱劑及抗焦慮症劑市場:2019∼2029年

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

出版商 Visiongain Ltd 商品編碼 835737
出版日期 內容資訊 英文 213 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗憂鬱劑及抗焦慮症劑市場:2019∼2029年 Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029
出版日期: 2019年03月29日內容資訊: 英文 213 Pages
簡介

全球抗憂鬱劑及抗焦慮症劑市場預計2018年達121億6,000萬美元。

本報告提供全球抗憂鬱劑及抗焦慮症劑市場相關調查,市場概要和各市場區隔趨勢,各地區趨勢,及加入此市場的主要企業的簡介等相關資訊彙整。

第1章 報告概要

第2章 抗憂鬱劑及抗焦慮症劑的簡介

  • 憂鬱和焦慮症的類型
  • 憂鬱和焦慮症的罹患率和死亡率簡介
  • 憂鬱引誘因素和預防
  • 抗憂鬱劑及抗焦慮症劑發展歷史
  • 抗憂鬱劑及抗焦慮症劑的主力級

第3章 全球市場:2018∼2029年

  • 2014年和2017年的收益
  • 市場區隔

第4章 各類藥物市場

  • 抗憂鬱藥選擇性血清素回收抑制劑(SSRIs)
  • 正腎上腺素與血清素回收抑制劑(SNRI)
  • 非典型抗精神病藥物
  • 三環系抗憂鬱藥
  • 血清素拮抗劑、再攝取抑制劑
  • 苯重氮基鹽
  • 單胺氧化酵素抑制劑
  • 其他

第5章 各適用市場

  • 重度憂鬱症
  • 廣泛性焦慮症
  • 恐慌症
  • 強迫症
  • 其他

第6章 各藥物類型市場

第7章 促進因素與阻礙因素

  • 推動市場的要素分析
  • 阻礙市場的要素分析

第8章 開發平台

第9章 主要國家市場

第10章 主要企業

第11章 市場定性分析

第12章 結論

目錄
Product Code: PHA0381

The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 213-page report you will receive 73 tables and 92 figures- all unavailable elsewhere.

The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029
  • Our investigation shows forecasts to 2029 for the following submarket by drug class:
  • Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Atypical Antipsychotics
  • Tricyclic Antidepressants (TCAs)
  • Serotonin Antagonist and Reuptake Inhibitors (SARIs)
  • Benzodiazepines
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Others
  • Our investigation shows forecasts to 2029 for the following submarket by indication:
  • Major Depressive Disorder (MDD)
  • General Anxiety Disorder (GAD)
  • Panic Disorder (PD)
  • Obsessive Compulsive Disorder (OCD)
  • Others
  • Our investigation shows forecasts to 2029 for the selected leading drugs:
  • Abilify
  • Abilify Maintena
  • Brintellix/Trintellix
  • Cipralex/Lexapro
  • Cymbalta
  • Invega Sustenna/ Xeplion/Trinza/Trevicta
  • Lamictal
  • Rexulti
  • Risperdal Consta
  • Zyprexa
  • This report provides individual revenue forecasts to 2029 for these regional and national markets:
  • North America: the US, Canada
  • Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
  • RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW
  • This report also provides discussion and qualitative analysis on:
  • Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
  • Antidepressant drugs pipeline analysis
  • Anti-anxiety drugs pipeline analysis
  • This report discusses the selected leading companies:
  • Allergan plc.
  • AstraZeneca plc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals
  • Key Questions Answered:
  • This report provides in-depth analysis of the antidepressant and anti-anxiety drugs market, identifying the latest trends and forecasting its growth and development over the coming 10 years.
  • The study addresses scope of the market in 2018 and assesses commercial drivers and restraints.
  • Through reading this report you will gain revenue forecasts from 2018 to 2029 for the overall world market and its leading submarkets, as well as regional and national markets.
  • This report provides revenue forecast for the leading antidepressant and anti-anxiety drugs from 2018 to 2019
  • Identify drug development trends that will affect market participants from 2018 to 2029.
  • See discussions of companies developing, manufacturing, and marketing antidepressant and ant-anxiety drugs, exploring products, technologies, R&D, partnerships, M&A and outlooks.

Visiongains study is intended for anyone requiring commercial analyses for the antidepressant and anti-anxiety drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of Findings
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who is This Study For?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to Antidepressant and Anti-anxiety Drugs

  • 2.1 Types of Depression and Anxiety Diseases
  • 2.2 Prevalence and Mortality Profiles for Depression and Anxiety Diseases
  • 2.3 Depression Contributing Factors and Prevention
  • 2.4. History of Antidepressant and Anti-anxiety Drugs Development
  • 2.5 Leading Classes of Antidepressant and Anti-anxiety Drugs
    • 2.5.1 Selective serotonin reuptake inhibitors (SSRIs)
    • 2.5.2 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
    • 2.5.3 Atypical Antipsychotics
    • 2.5.4 Tricyclic antidepressants (TCAs)
    • 2.5.5 Serotonin antagonist and reuptake inhibitors (SARIs)
    • 2.5.6 Benzodiazepines
    • 2.5.7 Monoamine Oxidase Inhibitors (MAOIs)
    • 2.5.8 Other

3. Antidepressant and Anti-anxiety Drugs: World Market 2018-2029

  • 3.1 Global Antidepressant and Anti-anxiety Drugs Revenues Plateau between 2014 and 2017
  • 3.2 Antidepressant and Anti-anxiety Drugs - Market Segmentation

4. Antidepressant and Anti-anxiety Drugs Market by Drug Class 2018-2029

  • 4.1 Selective serotonin reuptake inhibitors (SSRIs)
  • 4.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • 4.3 Atypical Antipsychotics
  • 4.4 Tricyclic antidepressants (TCAs)
  • 4.5 Serotonin Antagonist and Reuptake Inhibitors (SARIs)
  • 4.6 Benzodiazepines
  • 4.7 Monoamine Oxidase Inhibitors (MAOIs)
  • 4.8 Other

5. Antidepressant and Anti-anxiety Drugs Market by Indication 2018-2029

  • 5.1 Major Depressive Disorder (MDD)
  • 5.2 Generalized Anxiety Disorder (GAD)
  • 5.3 Panic Disorder (PD)
  • 5.4 Obsessive Compulsive Disorder (OCD)
  • 5.5 Others

6. Antidepressant and Anti-anxiety Drugs Market by Drug Type 2018-2029

  • 6.1 Invega Sustenna/Xeplion/Trinza/Trevicta
  • 6.2 LAMICTAL
  • 6.3 RISPERDAL CONSTA
  • 6.4 Cymbalta
  • 6.5 ABILIFY MAINTENA
  • 6.6 ABILIFY
  • 6.7 Zyprexa
  • 6.8 Rexulti
  • 6.9 Brintellix/Trintellix
  • 6.10 Cipralex/Lexapro

7. Drivers and Restraints in the Antidepressant and Anti-anxiety Drugs Market, 2018-2029

  • 7.1. Market Drivers Analysis
    • 7.1.1 Increasing Geriatric Population
    • 7.1.2 Launch of New Drugs is Expected to Drive the Market Growth
    • 7.1.3 Development of Advanced Antidepressant and Antianxiety Drugs
    • 7.1.4 Increasing Prevalence of Depression and Anxiety
    • 7.1.5 Escalating Mental Healthcare Awareness
  • 7.2 Market Restraints Analysis
    • 7.2.1 Social Stigma of Depression and Anxiety Diseases
    • 7.2.2 Increase in Generic Competition
    • 7.2.3 Stringent Regulatory Guidelines for New Drug Approval

8. Pipeline for Ant-depression and Anti-anxiety Drugs Market, 2018-2029

  • 8.1 Antidepressant Drugs Pipeline Analysis
    • 8.1.1 Esketamine
    • 8.1.2 Rapastinel (GLYX-13)
    • 8.1.3 SAGE-547
    • 8.1.4 ALKS 5461
  • 8.2 Anti-anxiety Drugs Pipeline Analysis
    • 8.2.1 Aloradine (PH94B)
    • 8.2.2 Tonmya (Cyclobenzaprine)
    • 8.2.3 AVN-101
    • 8.2.4 FKW00GA
    • 8.2.5 JNJ-42165279
    • 8.2.6 SRX246
    • 8.2.7 Travivo (Gepirone ER)
    • 8.2.8 Rexulti (Brexpiprazole)
    • 8.2.9 NBTX-001 (Xenon)

9. The Leading National Markets 2018-2029

  • 9.1 US and Europe Dominates the Global Antidepressant and Anti-anxiety Drugs Market
  • 9.2 Above-Average Growth in Emerging Markets: Regional Forecasts 2018-2029
  • 9.3 North America Antidepressant and Anti-anxiety Drugs Market
    • 9.3.1 The US: Leading Market for Antidepressant and Anti-anxiety Drugs
      • 9.3.1.1 The Antidepressant and Anti-anxiety Drugs Market in the U.S.
      • 9.3.1.2 Continued Dominance of the U.S. Market
    • 9.3.2 Canada Market Will Grow at High CAGR in North America Region
  • 9.4 The European Union Forms Second Largest Regional Market
    • 9.4.1 Increasing Prevalence of Chronic Diseases
    • 9.4.2 EU5: Ageing Populations to Drive Market Growth
    • 9.4.3 Germany is Leading the EU Antidepressant and Anti-anxiety Drugs Market
    • 9.4.4 UK Market is Propelled by the Government Initiatives for Mental Health
    • 9.4.5 France Antidepressant and Anti-anxiety Drugs is Projected to Grow at Lucrative CAGR
    • 9.4.6 Italy is Expected Showcase Positive Growth
    • 9.4.7 Spain Market is Projected to Grow at a Lucrative rate During 2018 - 2029
  • 9.5 Asia-Pacific Antidepressant and Anti-anxiety Drugs is Fastest Growing Market
    • 9.5.1 Japan - Still the Second Largest National Market
    • 9.5.1.1 Is the government of Japan doing enough to raise awareness and to prevent suicide?
    • 9.5.2 Chinese Antidepressant and Anti-anxiety Drugs Market
    • 9.5.2.1 China's Response: Major Efforts Over the Last Decade
    • 9.5.3 Indian Market to Expand by Double Growth Over the Forecast Period
    • 9.5.4 South Korean Market
  • 9.6 RoW Nation Sales Still Expanding - Market Forecast 2018-2029
    • 9.6.1 Brazilian Antidepressant and Anti-anxiety Drugs Market to Double in Size
    • 9.6.2 Mexico Antidepressant and Anti-anxiety Drugs Sales - Forecast 2018-2029
    • 9.6.3 Russia Antidepressant and Anti-anxiety Drugs
    • 9.6.4 South Africa Antidepressant and Anti-anxiety Drugs

10. Leading Companies in the Antidepressant and Antianxiety Drugs Market

  • 10.1 Johnson & Johnson
    • 10.1.1 Business Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Product Portfolio
    • 10.1.4 Recent Developments (2014-2017)
    • 10.1.5 SWOT Analysis
  • 10.2. Pfizer Inc.
    • 10.2.1 Business Overview
    • 10.2.2 Financial Overview
    • 10.2.3 Product Portfolio
    • 10.2.5 SWOT Analysis
  • 10.3. AstraZeneca
    • 10.3.1 Business Overview
    • 10.3.2 Financial Overview
    • 10.3.3 Product Portfolio
    • 10.3.4 Recent Developments
    • 10.3.5 SWOT Analysis
  • 10.4. Otsuka Pharmaceuticals
    • 10.4.1 Business Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Product Portfolio
    • 10.4.4 Recent Developments (2014-2018)
    • 10.4.5 SWOT Analysis
  • 10.5. Eli Lilly & Co.
    • 10.5.1 Business Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Product Portfolio
    • 10.5.4 Recent Developments 2018
    • 10.5.5 SWOT Analysis
  • 10.6. GlaxoSmithKline plc
    • 10.6.1 Business Overview
    • 10.6.2 Financial Overview
    • 10.6.3 Product Portfolio
    • 10.6.4 Recent Developments 2018
    • 10.6.5 SWOT Analysis
  • 10.7 H. Lundbeck A/S
    • 10.7.1 Business Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Product Portfolio
    • 10.7.4 Recent Developments (2014-2018)
    • 10.7.5 SWOT Analysis
  • 10.8. Allergan plc
    • 10.8.1 Business Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Product Portfolio
    • 10.8.4 Recent Developments (2014-2018)
    • 10.8.5 SWOT Analysis
  • 10.9. Takeda Pharmaceutical Company Limited
    • 10.9.1 Business Overview
    • 10.9.2 Financial Overview
    • 10.9.3 Product Portfolio
    • 10.9.4 Recent Developments (2014-2018)
    • 10.9.5 SWOT Analysis
  • 10.10. Bausch Health (Valeant Pharmaceuticals International)
    • 10.10.1 Business Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Product Portfolio
    • 10.10.4 Recent Developments
    • 10.10.5 SWOT Analysis

11. Qualitative Analysis of the Antidepressant and Anti-anxiety Drugs Industry and Market, 2018

  • 11.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats
  • 11.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antidepressant and Anti-anxiety Drugs Market
    • 11.2.1 Social Factors
    • 11.2.2 Technological Developments
    • 11.2.3 Economic Pressures
    • 11.2.4 Political Issues

12. Antidepressant and Anti-anxiety Drugs Market -2018-2029: Conclusions

  • 12.1 Blockbuster Antidepressant and Anti-anxiety Drugs in 2018 - Leading Brands
  • 12.2 The Leading Drug Class of Antidepressant and Anti-anxiety Drugs in 2018 and 2029
  • 12.3 Antidepressant and Anti-anxiety Drugs - Regional Market Changes
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Common Depression and Anxiety Diseases and Their Causes
  • Table 3.1 Antidepressant and Anti-anxiety Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2014-2017
  • Table 4.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Size ($bn) and Share (%), 2018
  • Table 4.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 5.1 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Size ($bn) and Share (%), 2018
  • Table 5.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 6.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Size ($bn) and Share (%), 2018
  • Table 6.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 8.1 Pipeline of Antidepressant Drugs - Phase III, 2017
  • Table 8.2 Pipeline of Antidepressant Drugs - Phase II, 2017
  • Table 8.3 Pipeline of Antidepressant Drugs - Phase II, 2017
  • Table 8.4 Pipeline of Antidepressant Drugs - Phase I, 2017
  • Table 8.5 Pipeline of Leading Anti-anxiety Drugs, 2017
  • Table 9.1 Antidepressant and Anti-anxiety Drugs Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2018
  • Table 9.2 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.3 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.4 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.5 U.S. Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.6 Canada Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.7 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.8 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.9 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.10 Germany Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.11 UK Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.12 France Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.13 Italy Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.14 Spain Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.15 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.16 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.17 Asia Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.18 Japan Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.19 China Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.20 Indian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.21 South Korea Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.22 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.23 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.24 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
  • Table 9.25 Brazilian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.26 Mexico Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.27 Russia Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 9.28 South Africa Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 10.1 Johnson & Johnson: Overview
  • Table 10.2 Johnson & Johnson: Product Portfolio
  • Table 10.3 Johnson & Johnson: Recent Developments
  • Table 10.4 Johnson & Johnson: Merger & Acquisition
  • Table 10.5 Pfizer Inc.: Overview
  • Table 10.6 Pfizer Inc.: Product Portfolio
  • Table 10.7 AstraZeneca: Overview
  • Table 10.8 AstraZeneca: Product Portfolio
  • Table 10.9 AstraZeneca: Recent Developments
  • Table 10.10 Otsuka: Overview
  • Table 10.11 Otsuka: Product Portfolio
  • Table 10.12 Otsuka: Recent Developments
  • Table 10.13 Lilly: Overview
  • Table 10.14 Lilly: Product Portfolio
  • Table 10.15 Lilly: Recent Developments
  • Table 10.16 GlaxoSmithKline: Overview
  • Table 10.17 GlaxoSmithKline: Product Portfolio
  • Table 10.18 GlaxoSmithKline: Recent Developments
  • Table 10.19 H. Lundbeck: Overview
  • Table 10.20 H. Lundbeck: Product Portfolio
  • Table 10.21 H. Lundbeck: Recent Developments
  • Table 10.22 H. Lundbeck: Strategic Collaboration
  • Table 10.23 Allergan: Overview
  • Table 10.24 Allergan: Product Portfolio
  • Table 10.25 Allergan: Recent Developments
  • Table 10.26 Takeda Pharmaceutical: Overview
  • Table 10.27 Takeda Pharmaceutical: Product Portfolio
  • Table 10.28 Takeda Pharmaceutical: Recent Developments
  • Table 10.27 Bausch Health: Recent Developments
  • Table 10.28 Bausch Health: Product Portfolio
  • Table 10.29 Bausch Health: Recent Developments
  • Table 11.1 Social, Technological, Economic, and Political Factors Affecting the Antidepressant and Anti-anxiety Drugs Market, 2018-2029

List of Figures

  • Figure 2.1 Cases of Depressive Disorder (in millions) by Region, 2015
  • Figure 2.2 Cases of Anxiety Disorder (in millions) by Region, 2015
  • Figure 3.1 Antidepressant and Anti-anxiety Drugs Historic Global Market Size ($bn), 2014-2017
  • Figure 3.2 Global Antidepressant and Anti-anxiety Drugs Market: Estimates and Forecasts Revenues ($bn), 2018-2029
  • Figure 4.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Drug Class
  • Figure 4.2 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2018
  • Figure 4.3 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2023
  • Figure 4.4 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2029
  • Figure 4.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues ($bn), 2018-2029
  • Figure 4.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues Share (%), 2018-2029
  • Figure 4.7 Global SSRIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.8 Global SNRIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.9 Global Atypical Antipsychotics Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.10 Global TCAs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.11 Global SARIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.12 Global Benzodiazepines Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.13 Global MAOIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 4.14 Global Other Drug Classes Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 5.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Indication
  • Figure 5.2 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2018
  • Figure 5.3 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2023
  • Figure 5.4 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2029
  • Figure 5.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Indication Revenues ($bn), 2018-2029
  • Figure 5.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Indication Revenues Share (%), 2018-2029
  • Figure 5.7 Global MDD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 5.8 Global GAD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 5.9 Global PD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 5.10 Global OCD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 5.11 Global Other Indications Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Drug Type
  • Figure 6.2 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2018
  • Figure 6.3 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2023
  • Figure 6.4 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2029
  • Figure 6.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Revenues ($bn), 2018-2029
  • Figure 6.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues Share (%), 2018-2029
  • Figure 6.7 Global Invega Sustenna/Xeplion/Trinza/Trevicta Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.8 Global LAMICTAL Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.9 Global RISPERDAL CONSTA Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.10 Global Cymbalta Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.11 Global ABILIFY MAINTENA Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.12 Global ABILIFY Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.13 Global Zyprexa Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.14 Global Rexulti Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.15 Global Brintellix /Trintellix Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
  • Figure 6.16 Global Cipralex/Lexapro Market: Estimates and Forecasts Revenues ($bn), 2018-2029
  • Figure 7.1 Antidepressant and Anti-anxiety Drugs Market: Drivers and Restraints, 2018-2029
  • Figure 9.1 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2018
  • Figure 9.2 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2023
  • Figure 9.3 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2029
  • Figure 9.4 U.S. Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), 2018-2029
  • Figure 9.5 Canada Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), 2018-2029
  • Figure 9.6 EU Antidepressant and Anti-anxiety Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2018-2029
  • Figure 9.7 EU Antidepressant and Anti-anxiety Drugs Market by Leading Country (EU5): Revenue Share Forecasts (%), 2018-2029
  • Figure 9.8 Germany Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.9 UK Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.10 France Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.11 Italy Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.12 Spain Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.13 Japan Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Growth Rate (%) 2018-2029
  • Figure 9.14 China Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.15 Indian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.16 South Korea Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.17 Antidepressant and Anti-anxiety Drugs Market in RoW: National Revenue Forecasts ($bn), 2018-2029
  • Figure 9.18 Antidepressant and Anti-anxiety Drugs Market in RoW: National Revenue Share Forecasts (%), 2018-2029
  • Figure 9.19 Brazilian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.20 Mexico Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.21 Russia Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 9.22 South Africa Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
  • Figure 10.1 Johnson & Johnson: Financial Overview 2014-2017
  • Figure 10.2 Johnson & Johnson: SWOT Analysis
  • Figure 10.3 Pfizer Inc.: Financial Overview 2014-2017
  • Figure 10.4 Pfizer Inc.: SWOT Analysis
  • Figure 10.5 AstraZeneca: Financial Overview 2014-2017
  • Figure 10.6 AstraZeneca: SWOT Analysis
  • Figure 10.7 Otsuka: Financial Overview 2014-2017
  • Figure 10.8 Otsuka: SWOT Analysis
  • Figure 10.9 Eli Lilly: Financial Overview 2014-2017
  • Figure 10.10 Eli Lilly: SWOT Analysis
  • Figure 10.11 GlaxoSmithKline: Financial Overview 2014-2017
  • Figure 10.12 GlaxoSmithKline: SWOT Analysis
  • Figure 10.13 H. Lundbeck: Financial Overview 2014-2017
  • Figure 10.14 H. Lundbeck: SWOT Analysis
  • Figure 10.15 Allergan: Financial Overview 2014-2017
  • Figure 10.16 Allergan: SWOT Analysis
  • Figure 10.17 Takeda Pharmaceutical: Financial Overview 2014-2017
  • Figure 10.18 Takeda Pharmaceutical: SWOT Analysis
  • Figure 10.19 Bausch Health: Financial Overview 2014-2017
  • Figure 10.20 Bausch Health: SWOT Analysis
  • Figure 11.1 Strengths and Weaknesses of the Antidepressant and Anti-anxiety Drugs Market, 2018-2029
  • Figure 11.2 Opportunities and Threats for The Antidepressant and Anti-anxiety Drugs Market, 2018-2029
  • Figure 12.1 Antidepressant and Anti-anxiety Drugs Market Forecasts: Regional Market Sizes ($bn), 2018-2029
  • Figure 12.2 Antidepressant and Anti-anxiety Drugs Market Forecasts: Regional Market Share (%), 2018-2029

Companies Listed

  • ACADIA Pharmaceuticals
  • Actelion, Ltd.
  • Alkermes
  • Alkermes Pharma Ireland Ltd.
  • Allergan plc.
  • Aptinyx
  • AstraZeneca plc.
  • Avineuro Pharmaceuticals
  • Axsome Therapeutics
  • Azevan Pharmaceuticals
  • Bausch Health
  • BioLite
  • BlackThorn Therapeutics
  • Bristol - Myers Squibb (BMS)
  • Cerecor
  • Denovo Biopharma
  • Eli Lilly and Company
  • Fabre-Kramer Pharmaceuticals
  • Forest Laboratories
  • GlaxoSmithKline plc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies
  • Janssen Pharmaceutica NV
  • Janssen Pharmaceuticals, Inc.
  • Janssen Research & Development
  • Johnson & Johnson (Janssen)
  • Lupin Pharmaceuticals
  • Luye Pharma (USA) Ltd.
  • Luye Pharma Group Ltd
  • Marinus Pharmaceuticals
  • Medtronic
  • Minerva Neurosciences
  • MSI Methylation Sciences
  • Neuralstem Inc.
  • Nobilis Therapeutics
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pherin Pharmaceuticals
  • Proteus Digital Health
  • Reviva Pharmaceuticals
  • Sage Therapeutics
  • Sandong Luye Pharmaceutical Co., Ltd.
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Suven Life Sciences
  • Taisho Pharmaceutical
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceuticals USA, Inc
  • Tonix Pharmaceuticals
  • Valeant Pharmaceuticals
  • VistaGen Therapeutics

List of Organizations Mentioned in the Report

  • Anxiety and Depression Association of America (ADAA)
  • Centers for Disease Control and Prevention (CDC)
  • European Medicines Agency (EMA)
  • European Union
  • Mental Health America
  • National Mental Health Institute (NIMH)
  • Organization for Economic Cooperation and Development (OECD)
  • The American Psychiatric Association (APA)
  • U.S. National Mental Health Institute
  • UK National Institute of Health and Clinical Excellence (NICE)
  • World Economic Forum (WEF)
  • World Health Organization (WHO)
Back to Top